Read more about the article MaxCyte Enters Strategic License Agreement with TG Therapeutics for Cell-Based Therapy Development
MaxCyte Enters Strategic License Agreement with TG Therapeutics for Cell-Based Therapy Development

MaxCyte Enters Strategic License Agreement with TG Therapeutics for Cell-Based Therapy Development

MaxCyte enters a strategic licensing agreement with TG Therapeutics for Flow Electroporation® technology to advance cell-based therapies.Quiver AI SummaryMaxCyte, Inc. announced a strategic platform license agreement with TG Therapeutics, a…

Continue ReadingMaxCyte Enters Strategic License Agreement with TG Therapeutics for Cell-Based Therapy Development

End of content

No more pages to load